What Happens If You Get Pregnant on Mounjaro

The decision to stop: why current guidance is clear

Discovering a pregnancy while on any prescription weight-loss medicine puts you in a situation most people are not prepared for, and the first feeling is often anxiety about whether harm has already occurred. The honest answer is that nobody can give you certainty either way at this stage, but the right next step is not in doubt.

Mounjaro is not licensed for use in pregnancy. This is not a cautious over-reach by regulators; it reflects a genuine gap in the evidence. Animal studies conducted during tirzepatide's development showed adverse effects on foetal development at doses relevant to human exposure. Because it would be unethical to run controlled pregnancy trials, that animal-study evidence is the closest available data, and it points firmly toward not using the medicine once pregnancy is confirmed.

Stopping Mounjaro promptly when you find out you are pregnant is the recommended course. Weight gained back during pregnancy is a clinical matter your obstetric team is experienced in managing; the priority shifts entirely to the pregnancy itself. Your GP or midwife can refer you to specialist support if weight management during pregnancy becomes relevant to your care. For broader context on how tirzepatide works and why pregnancy creates this specific concern, our guide to the Mounjaro injection covers the mechanism in plain terms.

The oral contraceptive question: a practical risk many people miss

One of the reasons some people find themselves in this situation is an interaction that is easy to overlook. Tirzepatide slows gastric emptying, which affects how the gut absorbs other medicines taken orally. For women using combined or progestogen-only oral contraceptive pills, this matters: UK guidance from NHS England and NHS Inform Scotland advises adding a non-oral method of contraception, such as condoms, for the first four weeks of Mounjaro treatment and for four weeks after every dose increase.

This is not a theoretical risk. The pill may not reach its normal absorption level during those windows, which reduces its reliability. Many people start Mounjaro without being told this clearly, particularly if the reminder comes in a leaflet rather than a conversation.

If you are already pregnant and looking back at when the gap might have occurred, this is the most common explanation our prescribers see. Going forward after this pregnancy, the MHRA and NHS England guidance on weight-management injection use and contraception is worth reading in full alongside a conversation with your GP. For questions about what the months after treatment look like more broadly, this page covers what to expect after stopping Mounjaro.

What is still uncertain and who should guide your care

The honest part of this conversation is acknowledging what nobody can tell you with confidence. There is no large-scale human registry data on tirzepatide exposure during early pregnancy. The foetal harm seen in animals occurred at specific doses and stages of development, and extrapolating that directly to a person who took one or two injections before a positive test is not straightforward. What clinicians can say is that the risk is considered sufficient to recommend stopping, not that every early exposure results in harm.

This is precisely why your GP and your obstetric team need to know about the Mounjaro use. They can document the timing, refer you for any appropriate monitoring, and make sure your antenatal care takes the full picture into account. Our page on what happens if you fall pregnant on Mounjaro sets out the steps to take and what to tell your clinical team in more detail. The MHRA's Yellow Card scheme also allows healthcare professionals and patients to report any suspected effects on a pregnancy from a medicine, which contributes to the evidence base over time.

There is no useful role for self-management here. The uncertainties involved require specialist input, and attempting to weigh up the animal data yourself will only deepen anxiety. Tell your midwife or GP at your earliest opportunity, ideally the same week you discover the pregnancy, and let them guide the monitoring plan. If disruption to your usual routine means you are unsure whether a dose was taken or missed around the time you conceived, our guidance on what happens if you forget to take your Mounjaro explains how missed doses work and is worth reading alongside advice from your clinical team.

Planning ahead: contraception, wash-out, and returning to treatment

For anyone on Mounjaro who is not currently trying to conceive, the most useful thing this situation illustrates is how important reliable contraception is during treatment. The MHRA advises using effective contraception while taking GLP-1 medicines, and for tirzepatide specifically, that means addressing the oral-pill absorption window at every dose increase — not just at the start.

If, after this pregnancy, you plan to return to weight-loss treatment, that is a conversation to have with your prescriber when the time is right. The question of when it is safe to restart tirzepatide after giving birth, particularly for anyone who wants to breastfeed, is one where current guidance recommends against use while breastfeeding (animal studies show tirzepatide passes into milk). Your prescriber can help you think through timing. Our full Mounjaro overview covers the licensed eligibility criteria and what the private treatment pathway looks like when you are ready.

If you have questions in the meantime and would prefer to speak with a prescriber directly rather than wait for a GP appointment, our clinical team is available to help you think through next steps. You might also find it reassuring to read about how our pharmacy operates and the clinical oversight it involves. Separately, practical questions like what to do if a Mounjaro pen has been exposed to heat, which sometimes comes up when people are managing disruption to their routine during early pregnancy, are answered in our guide on what happens if Mounjaro gets hot.